Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Unfractionated heparin (UFH) is a naturally occurring, heterogeneous mixture of sulfated glycosaminoglycans used as an anticoagulant. It acts primarily by potentiating antithrombin III’s inhibition of key coagulation enzymes. Its clinical utility lies in its rapid onset but requires careful monitoring due to variability in response and significant risks including bleeding complications and HIT. Its effects can be rapidly reversed if needed.
Binds to and activates antithrombin III, which then inhibits thrombin (Factor IIa) and Factor Xa, thereby preventing clot formation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Unfractionated Heparin (UFH).